The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action

Bibliography

• Hovi T, Stenvik M. Surveillance of patients with acute flaccid paralysis in Finland: report of a pilot study. Bull World Health Organ 2000;12:298-304
   Google Scholar
• Olive JM, Castillo C, Castro RG, de Quadros CA. Epidemiologic study of Guillain-Barre syndrome in children < 15 years of age in Latin America. J Infect Dis 1997;175(Suppl 1):S160-4
   Google Scholar
• Guillain G, Barre JA, Strohl A. Sur un syndrome de radiculonevrite avec hyperalbuminose du liquide cephalo-rachidien sans reaction cellulaire: remarques sur les caracteres cliniques et graphiques des reflexes tendineux. Bulletins et memoires de la Societe des Medecins des Hopitaux de Paris 1916;40:1462-70
   Google Scholar
• van Koningsveld R, van Doorn PA, Schmitz PI, Mild forms of Guillain-Barre syndrome in an epidemiologic survey in the Netherlands. Neurology 2000;54:620-5
   PubMed Web of Science ®Google Scholar
• Govoni V, Granieri E. Epidemiology of the Guillain-Barre syndrome. Curr Opin Neurol 2001;14:605-13
   PubMed Web of Science ®Google Scholar
• Chio A, Cocito D, Leone M, Guillain-Barre syndrome: a prospective, population-based incidence and outcome survey. Neurology 2003;60:1146-50
   PubMed Web of Science ®Google Scholar
• Bogliun G, Beghi E. Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand 2004;110:100-6
   PubMed Web of Science ®Google Scholar
• Hafer-Macko C, Hsieh ST, Li CY, Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-44
   PubMed Web of Science ®Google Scholar
• Hafer-Macko CE, Sheikh KA, Li CY, Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996;39:625-35
   PubMed Web of Science ®Google Scholar
• Ho TW, Mishu B, Li CY, Guillain-Barre syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118:597-605
   PubMed Web of Science ®Google Scholar
• Hadden RDM, Cornblath DR, Hughes RAC, ; Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Ann Neurol 1998;44:780-8
   PubMed Web of Science ®Google Scholar
• McKhann GM, Cornblath DR, Griffin JW, Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333-42
   PubMed Web of Science ®Google Scholar
• Ogawara K, Kuwabara S, Mori M, Axonal Guillain-Barre syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000;48:624-31
   PubMed Web of Science ®Google Scholar
• Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barre syndrome: a reappraisal. Ann Neurol 1999;46:701-7
   PubMed Web of Science ®Google Scholar
• Kalita J, Misra UK, Das M. Neurophysiological criteria in the diagnosis of different clinical types of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2008;79:289-93
   PubMed Web of Science ®Google Scholar
• Kushnir M, Klein C, Pollak L, Rabey JM. Evolving pattern of Guillain-Barre syndrome in a community hospital in Israel. Acta Neurol Scand 2008;117:347-50
   PubMedGoogle Scholar
• Islam Z, Jacobs BC, van Belkum A, Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology 2010;74:581-7
   PubMed Web of Science ®Google Scholar
• Kokubun N, Nishibayashi M, Uncini A, Conduction block in acute motor axonal neuropathy. Brain 2010;133:2897-908
   PubMed Web of Science ®Google Scholar
• Uncini A, Yuki N. Electrophysiologic and immunopathologic correlates in Guillain-Barre syndrome subtypes. Expert Rev Neurother 2009;9:869-84
   PubMed Web of Science ®Google Scholar
• Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956;255:57-65
   PubMed Web of Science ®Google Scholar
• Bickerstaff ER. Brain-stem encephalitis; further observations on a grave syndrome with benign prognosis. Br Med J 1957;1:1384-7
   PubMed Web of Science ®Google Scholar
• Bickerstaff ER, Cloake PC. Mesencephalitis and rhombencephalitis. Br Med J 1951;2:77-81
   PubMed Web of Science ®Google Scholar
• Ito M, Kuwabara S, Odaka M, Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol 2008;255:674-82
   PubMed Web of Science ®Google Scholar
• Odaka M, Yuki N, Yamada M, Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain 2003;126:2279-90
   PubMed Web of Science ®Google Scholar
• Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. Guillain-Barre syndrome variants in Emilia-Romagna, Italy, 1992-3: incidence, clinical features, and prognosis. J Neurol Neurosurg Psychiatry 1998;65:218-24
   PubMedGoogle Scholar
• Lyu RK, Tang LM, Cheng SY, Guillain-Barre syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry 1997;63:494-500
   PubMed Web of Science ®Google Scholar
• Mori M, Kuwabara S, Fukutake T, Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001;56:1104-6
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Swan AV, Raphael JC, Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain 2007;130:2245-57
   PubMed Web of Science ®Google Scholar
• Jacobs BC, Rothbarth PH, van der Meche FGA, The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology 1998;51:1110-15
   PubMed Web of Science ®Google Scholar
• Winer JB, Hughes RAC, Anderson MJ, A prospective study of acute idiopathic neuropathy: II. antecedent events. J Neurol Neurosurg Psychiatry 1988;51:613-18
   PubMed Web of Science ®Google Scholar
• Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni infection and Guillain-Barre syndrome. N Engl J Med 1995;333:1374-9
   PubMed Web of Science ®Google Scholar
• Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect Dis 2001;1:29-37
   PubMedGoogle Scholar
• Yuki N, Susuki K, Koga M, Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci USA 2004;101:11404-9
   PubMed Web of Science ®Google Scholar
• Yuki N, Sato S, Inuzuka T, Axonal degeneration in the Guillain-Barre syndrome and anti-GM1 ganglioside antibodies. Muscle Nerve 1992;15:116
   PubMedGoogle Scholar
• Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990;40:1900-2
   PubMed Web of Science ®Google Scholar
• Kusunoki S, Chiba A, Kon K, N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barre syndrome. Ann Neurol 1994;35:570-6
   PubMed Web of Science ®Google Scholar
• Kusunoki S, Iwamori M, Chiba A, GM1b is a new member of antigen for serum antibody in Guillain-Barre syndrome. Neurology 1996;47:237-42
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Ogawara K, Misawa S, Does Campylobacter jejuni infection elicit “demyelinating” Guillain-Barre syndrome? Neurology 2004;63:529-33
   PubMed Web of Science ®Google Scholar
• Yuki N, Taki T, Inagaki F, A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 1993;178:1771-5
   PubMed Web of Science ®Google Scholar
• Koga M, Gilbert M, Takahashi M, Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre syndrome after Campylobacter jejuni enteritis. J Infect Dis 2006;193:547-55
   PubMed Web of Science ®Google Scholar
• Susuki K, Nishimoto Y, Yamada M, Acute motor axonal neuropathy rabbit model: immune attack on nerve root axons. Ann Neurol 2003;54:383-8
   PubMed Web of Science ®Google Scholar
• Yuki N, Yamada M, Koga M, Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001;49:712-20
   PubMed Web of Science ®Google Scholar
• Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barre syndrome. N Engl J Med 1995;333:1374-9
   PubMed Web of Science ®Google Scholar
• Shahrizaila N, Yuki N. Guillain-Barre syndrome animal model: the first proof of molecular mimicry in human autoimmune disorder. J Biomed Biotechnol 2011;2011:829129 15 December 2010 [Epub ahead of print]
   Google Scholar
• Susuki K, Rasband MN, Tohyama K, Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007;27:3956-67
   PubMed Web of Science ®Google Scholar
• Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677-9
   PubMed Web of Science ®Google Scholar
• Chiba A, Kusunoki S, Obata H, Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-17
   PubMed Web of Science ®Google Scholar
• Willison HJ, Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J Neuroimmunol 1994;50:159-65
   PubMed Web of Science ®Google Scholar
• Yuki N, Sato S, Tsuji S, An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J Neurol Sci 1993;118:83-7
   PubMed Web of Science ®Google Scholar
• Koga M, Ang CW, Yuki N, Comparative study of preceding Campylobacter jejuni infection in Guillain-Barre syndrome in Japan and The Netherlands. J Neurol Neurosurg Psychiatry 2001;70:693-5
   PubMedGoogle Scholar
• Koga M, Gilbert M, Li J, Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology 2005;64:1605-11
   PubMed Web of Science ®Google Scholar
• Kimoto K, Koga M, Odaka M, Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies. Neurology 2006;67:1837-43
   PubMed Web of Science ®Google Scholar
• Houliston RS, Koga M, Li J, A Haemophilus influenzae strain associated with Fisher syndrome expresses a novel disialylated ganglioside mimic. Biochemistry 2007;46:8164-71
   PubMed Web of Science ®Google Scholar
• Chiba A, Kusunoki S, Obata H, Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-17
   PubMed Web of Science ®Google Scholar
• Liu JX, Willison HJ, Pedrosa-Domellof F. Immunolocalisation of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci 2009;50(7):3226-32 28 Feb 2009 [Epub ahead of print]
   Google Scholar
• Kuwabara S, Asahina M, Nakajima M, Special sensory ataxia in Miller Fisher syndrome detected by postural body sway analysis. Ann Neurol 1999;45:533-6
   PubMed Web of Science ®Google Scholar
• Yuki N. Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome). J Neuroimmunol 2009;215:1-9
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Swan AV, van Doorn PA. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev 2010:CD001446
   PubMed Web of Science ®Google Scholar
• Guillain-Barre Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Lancet 1993;341:586-90
   PubMed Web of Science ®Google Scholar
• van Koningsveld R, Schmitz PI, van der Meche FGA, Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 2004;363:192-6
   PubMed Web of Science ®Google Scholar
• Susuki K, Yuki N. Effect of methylprednisolone in patients with Guillain-Barre syndrome. Lancet 2004;363:1236-7; author reply 1237-8
   PubMedGoogle Scholar
• Rubinstein MA, Kagan BM, Macgillviray MH, Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions. Ann Intern Med 1959;51:1409-19
   PubMed Web of Science ®Google Scholar
• Brettle RP, Gross M, Legg NJ, Treatment of acute polyneuropathy by plasma exchange. Lancet 1978;2:1100
   PubMed Web of Science ®Google Scholar
• Gross ML, Legg NJ, Lockwood MC, Pallis C. The treatment of inflammatory polyneuropathy by plasma exchange. J Neurol Neurosurg Psychiatry 1982;45:675-9
   PubMedGoogle Scholar
• Server AC, Lefkowith J, Braine H, McKhann GM. Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange. Ann Neurol 1979;6:258-61
   PubMed Web of Science ®Google Scholar
• Rumpl E, Mayr U, Gerstenbrand F, Treatment of Guillain-Barre syndrome by plasma exchange. J Neurol 1981;225:207-17
   PubMedGoogle Scholar
• The Guillain-Barre syndrome Study Group. Plasmapheresis and acute Guillain-Barre syndrome. Neurology 1985;35:1096-104
   PubMed Web of Science ®Google Scholar
• The French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. Ann Neurol 1987;22:753-61
   PubMedGoogle Scholar
• The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Appropriate number of plasma exchanges in Guillain-Barre syndrome. Ann Neurol 1997;41:298-306
   PubMed Web of Science ®Google Scholar
• Yuki N, Tagawa Y, Hirata K. Minimal number of plasma exchanges needed to reduce immunoglobulin in Guillain-Barre syndrome. Neurology 1998;51:875-7
   PubMedGoogle Scholar
• Greenshields KN, Halstead SK, Zitman FM, The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest 2009;119:595-610
   PubMed Web of Science ®Google Scholar
• Goodfellow JA, Bowes T, Sheikh K, Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci 2005;25:1620-8
   PubMed Web of Science ®Google Scholar
• Lehmann HC, Lopez PH, Zhang G, Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J Neurosci 2007;27:27-34
   PubMedGoogle Scholar
• Lopez G, Zhang J, Zhang HC, Passive transfer of IgG anti-GM1 antibodies impairs peripheral nerve repair. J Neurosci 2010;30:9533-41
   PubMedGoogle Scholar
• Cornblath DR, Hughes RAC. Treatment for Guillain-Barre syndrome. Ann Neurol 2009;66:569-70
   PubMedGoogle Scholar
• Kleyweg RP, van der Meche FGA, Meulstee J. Treatment of Guillain-Barre syndrome with high-dose gammaglobulin. Neurology 1988;38:1639-41
   PubMed Web of Science ®Google Scholar
• van der Meche FGA, Schmitz PI, Dutch Guillain-Barre Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 1992;326:1123-9
   PubMed Web of Science ®Google Scholar
• Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet 1997;349:225-30
   PubMed Web of Science ®Google Scholar
• Korinthenberg R, Monting JS. Natural history and treatment effects in Guillain-Barre syndrome: a multicentre study. Arch Dis Child 1996;74:281-7, Apr 1996
   PubMed Web of Science ®Google Scholar
• Gurses N, Uysal S, Cetinkaya F, Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome. Scand J Infect Dis 1995;27:241-3
   PubMed Web of Science ®Google Scholar
• Korinthenberg R, Schessl J, Kirschner J, Monting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial. Pediatrics 2005;116:8-14
   PubMed Web of Science ®Google Scholar
• Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC. Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 2001;71:235-8
   PubMedGoogle Scholar
• Kuitwaard K, de Gelder J, Tio-Gillen AP, Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol 2009;66:597-603
   PubMed Web of Science ®Google Scholar
• Jacobs BC, van Doorn PA, Schmitz PI, Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome. Ann Neurol 1996;40:181-7
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Mori M, Ogawara K, Intravenous immunoglobulin therapy for Guillain-Barre syndrome with IgG anti-GM1 antibody. Muscle Nerve 2001;24:54-8
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004;291:2367-75
   PubMed Web of Science ®Google Scholar
• Nishimoto Y, Koga M, Kamijo M, Immunoglobulin improves a model of acute motor axonal neuropathy by preventing axonal degeneration. Neurology 2004;62:1939-44
   PubMed Web of Science ®Google Scholar
• Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol 2002;51:673-80
   PubMed Web of Science ®Google Scholar
• Zhang G, Lopez PH, Li CY, Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004;127:1085-100
   PubMed Web of Science ®Google Scholar
• Overell JR, Hsieh ST, Odaka M, Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev 2007:CD004761
   Google Scholar
• Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 2007;68:1144-6
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2010;6:CD002063
   PubMedGoogle Scholar
• Ruts L, Drenthen J, Jacobs BC, van Doorn PA. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010;74:1680-6
   PubMed Web of Science ®Google Scholar
• Yuki N, Kuwabara S. Axonal Guillain-Barre syndrome: carbohydrate mimicry and pathophysiology. J Peripher Nerv Syst 2007;12:238-49
   PubMedGoogle Scholar
• Phongsisay V, Susuki K, Matsuno K, Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome. J Neuroimmunol 2008;205:101-4
   PubMed Web of Science ®Google Scholar
• Halstead SK, Zitman FM, Humphreys PD, Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008;131:1197-208
   PubMed Web of Science ®Google Scholar
• van Koningsveld R, Steyerberg EW, Hughes RAC, A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol 2007;6:589-94
   PubMed Web of Science ®Google Scholar